The SpectraCure systems with IDOSE® is a sophisticated laser equipment with optical fibers and dosimetry. The systems allows pretreatment planning including optimal optical fibre positioning and optimal light dose calculation. During IPDT, IDOSE® also performs real-time adjustments to the dosimetry plan covering the different parts of the target tissue to ensure that the entire tumour is treated while sparing the surrounding organs at risk.

With the SpectraCure systems with IDOSE®, the risk of treatment failures due to inter- or intra-patient variations has the potential to be significantly reduced.

SpectraCure's technology allows tomographic mapping of the optical light dose build-up (the in different parts of the lesion.

The SpectraCure systems with IDOSE® has the potential to become the tool that makes interstitial PDT and thermal treatment accurate, precise and safe for each patient independent thanks to:

The SpectraCure Laser Device and Dosimetry Platform

Accuracy - The SpectraCure systems with IDOSE® has the potential to reduce treatment failures and enable the best possible treatment outcome of individual patients independent of tumour tissue variations. This is because the light dose from each individual optical fibre is monitored in real time together with other treatment-related parameters to allow dose plan adjustment of each separate optical fibre.

Precision - The SpectraCure systems with IDOSE® is a truly a local treatment as it occurs only in the planned area.

Individualised dosimetry - damage to tissue surrounding the localised treatment site can potentially be minimized by The SpectraCure system with IDOSE® because it is possible to monitor and adjust the light dose from each individual optical fibre.

Safety - localised areas of cancer can potentially be destroyed by The SpectraCure systems with IDOSE® without the cumulative toxicity associated with, e.g. ionizing radiation.

1 - Injection of photosensitiser.

2 - Predose planning including calculation of optimal fibre positioning and calculation of optimum light dose per optical fibre.

3 - Accurate positioning of the optical fibres within the tumour.

4 - Therapeutic light delivery to the target tissue and activation of the photosensitiser.

5 - Real-time monitoring of relevant PDT parameters such as light dose, photosensitiser concentration and tissue oxygenation level.

6 - Updating of the dosimetry plan in real time to, e.g. ensure the correct light dose from each individual optical fibre.
A. Prostate

B. Bladder

C. Endorectal ultrasound probe

D. Template guiding needle position

E. Rectum
A typical treatment involves: